LONDON, April 24, 2023 /PRNewswire/ -- Smith+Nephew
(LSE:SN, NYSE:SNN), the global medical technology company, today
introduced its new CORI™ Digital Tensioner - a purpose
built device that lets surgeons measure the ligament tension in a
knee prior to cutting bone.1 By enabling a surgeon to
quantify joint laxity in the native knee and achieve an optimal
ligament tensioning force, the CORI Digital Tensioner helps to
reduce variability when balancing the knee in
surgery.1-4 This helps make surgical planning more
objective versus other commercially available
alternatives.1,3
Personalizing Surgery and Helping Reduce Variability in
Robotics-assisted TKA
The CORI Digital Tensioner produces a
surgeon-defined, quantifiable force to distract the knee joint,
apply consistent tension to the ligaments, and provide objective
gap data for procedure planning and execution.1,3 A
small clinical case series showed the CORI Digital Tensioner
reduced variability of tensioning by 64% when compared to a manual
technique.5*
"I've never seen anything like the digital tensioner before,"
stated Dr. Steven Haas at Hospital
for Special Surgery in New York.
"You try to teach how much force to apply, but it varies by surgeon
and from one case to another. The CORI Digital Tensioner goes into
the knee, you see a force or load being applied, and the gap it
created. This technology is something I've wanted for the last
twenty years."
Advancing procedural innovation in robotic-assisted surgery, the
CORI Digital Tensioner is a differentiated technology that helps
solve challenges for surgeons, including:
- The first and only ligament tensioning device in
robotic-assisted surgery to assess joint laxity in the native knee
before performing bony resection.
- Automatic collection of gap data at a specified force through
the full range of movement.
- A true tensioning device using a software interface that allows
surgeons to choose their preferred target force value (50±10N,
100±10N, or 150±10N).
The first commercial surgical procedure using the CORI Digital
Tensioner was recently performed by Dr. Bertrand Kaper of Orthopedic Specialists of
Scottsdale and HONORHEALTH
Medical Group in Arizona.
"The integration of this dedicated soft tissue tensioning device
brings a new realm of objective data to the technique of knee
replacement," commented Dr. Kaper. "The surgeon is now able to
collect joint laxity data, in a proactive manner, to assist with
the visualization, planning and execution of the patient's surgery
in real time. It's unlike any other tool we've historically had
available and will be a powerful addition to the robotic-assisted
knee replacement technology that the CORI™ platform
currently offers."
To learn more about the latest advancements in orthopaedic
reconstruction and discover more about robotics and computer-guided
solutions, please go to
https://www.smith-nephew.com/en-us/health-care-professionals/products/orthopaedics/cori
* n=4
References
- Smith+Nephew 2022. Optimus TKA Tensioner Gap Assessment
Verification Report. Internal Report. 10059269.
- Smith+Nephew 2021. Tensioner Design Verification Test Report.
Internal Report. TR100123
- Smith+Nephew 2022. Tensioner KPC: Tensioner Calibration Check.
Internal Report. TR100116, Rev.B
- Haas SB, Chow J, Nathwani D, Belooshi A, et al.
Smith+Nephew CORI™ Digital Tensioner for total knee
arthroplasty (TKA): ligament tensioning and assessment prior to
bone resections. S+N Evidence in Focus Whitepaper. 2022 Dec.
- Smith+Nephew 2022. Tensioner Whitepaper Supporting Evidence.
Internal Report. 10073166 REV A.
About Smith+Nephew
Smith+Nephew is a portfolio medical
technology company focused on the repair, regeneration and
replacement of soft and hard tissue. We exist to restore people's
bodies and their self-belief by using technology to take the limits
off living. We call this purpose 'Life Unlimited'. Our 19,000
employees deliver this mission every day, making a difference to
patients' lives through the excellence of our product
portfolio, and the invention and application of new technologies
across our three global franchises of Orthopaedics, Sports
Medicine & ENT and Advanced Wound Management.
Founded in Hull, UK, in 1856,
we now operate in more than 100 countries, and generated annual
sales of $5.2 billion in 2022.
Smith+Nephew is a constituent of the FTSE100 (LSE:SN, NYSE:SNN).
The terms 'Group' and 'Smith+Nephew' are used to refer to Smith
& Nephew plc and its consolidated subsidiaries, unless the
context requires otherwise.
For more information about Smith+Nephew, please
visit www.smith-nephew.com and follow us
on Twitter, LinkedIn, Instagram or Facebook.
Forward-looking Statements
This document may
contain forward-looking statements that may or may not prove
accurate. For example, statements regarding expected revenue growth
and trading margins, market trends and our product pipeline are
forward-looking statements. Phrases such as "aim", "plan",
"intend", "anticipate", "well-placed", "believe", "estimate",
"expect", "target", "consider" and similar expressions are
generally intended to identify forward-looking statements.
Forward-looking statements involve known and unknown risks,
uncertainties and other important factors that could cause actual
results to differ materially from what is expressed or implied by
the statements. For Smith+Nephew, these factors include: risks
related to the impact of Covid, such as the depth and longevity of
its impact, government actions and other restrictive measures taken
in response, material delays and cancellations of elective
procedures, reduced procedure capacity at medical facilities,
restricted access for sales representatives to medical facilities,
or our ability to execute business continuity plans as a result of
Covid; economic and financial conditions in the markets we serve,
especially those affecting healthcare providers, payers and
customers (including, without limitation, as a result of Covid);
price levels for established and innovative medical devices;
developments in medical technology; regulatory approvals,
reimbursement decisions or other government actions; product
defects or recalls or other problems with quality management
systems or failure to comply with related regulations; litigation
relating to patent or other claims; legal and financial compliance
risks and related investigative, remedial or enforcement actions;
disruption to our supply chain or operations or those of our
suppliers (including, without limitation, as a result of Covid);
competition for qualified personnel; strategic actions, including
acquisitions and dispositions, our success in performing due
diligence, valuing and integrating acquired businesses; disruption
that may result from transactions or other changes we make in our
business plans or organisation to adapt to market developments;
relationships with healthcare professionals; reliance on
information technology and cybersecurity; disruptions due to
natural disasters, weather and climate change related events;
changes in customer and other stakeholder sustainability
expectations; changes in taxation regulations; effects of foreign
exchange volatility; and numerous other matters that affect us or
our markets, including those of a political, economic, business,
competitive or reputational nature. Please refer to the documents
that Smith+Nephew has filed with the U.S. Securities and Exchange
Commission under the U.S. Securities Exchange Act of 1934, as
amended, including Smith+Nephew's most recent annual report on Form
20-F, which is available on the SEC's website at www.
sec.gov, for a discussion of certain of these factors. Any
forward-looking statement is based on information available to
Smith+Nephew as of the date of the statement. All written or oral
forward-looking statements attributable to Smith+Nephew are
qualified by this caution. Smith+Nephew does not undertake any
obligation to update or revise any forward-looking statement to
reflect any change in circumstances or in Smith+Nephew's
expectations.
™ Trademark of Smith+Nephew. Certain marks registered in US
Patent and Trademark Office.
Photo -
https://mma.prnewswire.com/media/2060359/Smith_and_Nephew_CORI_Tensioner.jpg
Logo -
https://mma.prnewswire.com/media/3924/Smith_Nephew_Logo.jpg
View original
content:https://www.prnewswire.co.uk/news-releases/smithnephew-introduces-first-of-its-kind-handheld-digital-tensioning-device-for-robotically-enabled-total-knee-arthroplasty-301804410.html